Q-omics provides the consensus-scored B3GALT5 profile across patient tissues and cancer cell-line models. B3GALT5 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, B3GALT5 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, B3GALT5 RNA expression shows 15,661 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, HNSC, and KIRP as cancer lineages where B3GALT5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B3GALT5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B3GALT5 survival associations across molecular data types. B3GALT5 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B3GALT5 RNA expression–survival associations across cancer types. High B3GALT5 expression shows unfavorable associations in UVM, LGG, SKCM and THCA, but favorable associations in CESC and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for B3GALT5 RNA expression.
This table summarizes B3GALT5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for B3GALT5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B3GALT5 shows lower tumor expression in HNSC, COAD, THCA and KICH and higher tumor expression in KIRP and LUSC. The HNSC box plot shows higher B3GALT5 RNA expression in normal versus tumor tissue (log2 FC = −1.075, t-test p < 0.001).
This table shows molecular features associated with B3GALT5 in patient tissues and cancer cell lines. In patient samples, B3GALT5 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, B3GALT5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
